To estimate rates of resistance to first-line anti-TB drugs, including monoresistance to isoniazid (Hr-TB) and rifampicin (RR-TB), and rates of MDR-TB among TB cases in Almaty, Kazakhstan, and to examine factors associated with TB, Hr-TB, and MDR-TB diagnosis, particularly focusing on the implications for treatment strategies.
Key Findings:
Kazakhstan has a high burden of MDR-TB, with stable rates over the last two decades, posing significant public health challenges.
WHO estimates indicate significant rates of Hr-TB and MDR-TB in Kazakhstan, necessitating urgent intervention.
This study provides the first estimates of Hr-TB in Kazakhstan, filling a critical knowledge gap and highlighting the need for targeted public health strategies.
Interpretation:
Understanding the prevalence of Hr-TB and MDR-TB is essential for effective treatment and public health policy in high-burden regions like Kazakhstan, where immediate action is required to mitigate the impact of these resistant strains.
Limitations:
The study only includes data from Almaty, which may not represent the entire country, potentially limiting the generalizability of the findings.
Potential biases in self-reported patient histories could affect the accuracy of the data collected.
Conclusion:
This study highlights the urgent need for improved surveillance and treatment strategies for drug-resistant TB in Kazakhstan.
